全文获取类型
收费全文 | 44452篇 |
免费 | 3812篇 |
国内免费 | 1349篇 |
专业分类
耳鼻咽喉 | 218篇 |
儿科学 | 951篇 |
妇产科学 | 544篇 |
基础医学 | 7285篇 |
口腔科学 | 1031篇 |
临床医学 | 3116篇 |
内科学 | 7206篇 |
皮肤病学 | 937篇 |
神经病学 | 3659篇 |
特种医学 | 678篇 |
外国民族医学 | 5篇 |
外科学 | 3363篇 |
综合类 | 5958篇 |
现状与发展 | 4篇 |
预防医学 | 2044篇 |
眼科学 | 538篇 |
药学 | 6717篇 |
3篇 | |
中国医学 | 2159篇 |
肿瘤学 | 3197篇 |
出版年
2023年 | 753篇 |
2022年 | 1082篇 |
2021年 | 1672篇 |
2020年 | 1548篇 |
2019年 | 1741篇 |
2018年 | 1713篇 |
2017年 | 1607篇 |
2016年 | 1439篇 |
2015年 | 1515篇 |
2014年 | 2533篇 |
2013年 | 2738篇 |
2012年 | 2303篇 |
2011年 | 2768篇 |
2010年 | 2190篇 |
2009年 | 2184篇 |
2008年 | 2205篇 |
2007年 | 1989篇 |
2006年 | 1817篇 |
2005年 | 1722篇 |
2004年 | 1621篇 |
2003年 | 1496篇 |
2002年 | 1315篇 |
2001年 | 988篇 |
2000年 | 942篇 |
1999年 | 834篇 |
1998年 | 642篇 |
1997年 | 614篇 |
1996年 | 524篇 |
1995年 | 510篇 |
1994年 | 450篇 |
1993年 | 333篇 |
1992年 | 267篇 |
1991年 | 276篇 |
1990年 | 210篇 |
1989年 | 182篇 |
1988年 | 185篇 |
1987年 | 142篇 |
1986年 | 154篇 |
1985年 | 329篇 |
1984年 | 312篇 |
1983年 | 242篇 |
1982年 | 273篇 |
1981年 | 214篇 |
1980年 | 199篇 |
1979年 | 181篇 |
1978年 | 135篇 |
1977年 | 94篇 |
1976年 | 103篇 |
1975年 | 91篇 |
1973年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
61.
目的 明确miR-218在胶质瘤组织中的表达,探讨其对胶质瘤血管生成的作用及机制。方法 采用荧光实时定量PCR法和免疫印迹法检测胶质瘤组织和细胞中miR-218、P70核糖体S6激酶1(p70s6k1)的表达情况,采用基质胶塞实验和小管形成实验分别在体内外检测miR-218对新血管生成的影响。结果 21例胶质瘤组织标本中miR-218表达较7例癌旁组织标本明显下调,且表达量与WHO分级有关。过表达miR-218能显著抑制血管生成。MiR-218直接靶向p70s6k1。过表达p70s6k1能部分逆转miR-218对血管新生的抑制作用。结论 MiR-218能通过靶向p70s6k1的表达调控胶质瘤血管生成,进而影响胶质瘤的进展。 相似文献
62.
目的:观察清热通利汤对于宫颈炎合并人乳头瘤病毒(HPV)感染患者生化指标与临床症状的功效。方法:选取86例宫颈炎合并HPV感染患者作为观察资料,选取的患者按简单随机原则以数字表平均划分为对照组与治疗组,对照组给予常规治疗,治疗组给予清热通利汤外用; 治疗后3个月,对比临床疗效,统计临床症状的缓解时间; 评估治疗前、后患者生化指标、中医证候积分、血清炎性因子的变化情况。结果:治疗组显效率为53.49%、总有效率为95.35%,对照组依次为37.21%、72.09%,治疗组临床疗效优于对照组(P<0.05)。治疗后,治疗组患者HPV-DNA转阴率高于对照组,HPV-DNA转阴时间、HPV病毒载量均低于对照组,差异均有统计学意义(P<0.05); 治疗组患者宫颈柱状上皮异位、接触性出血、阴道清洁度异常、白带化验异常的消退时间均短于对照组(P<0.05); 治疗后两组患者各项中医证候积分、血清炎性因子与生化指标均较治疗前改善且治疗组均优于对照组(P<0.05)。结论:清热通利汤能够促进宫颈炎合并HPV感染患者HPV-DNA转阴,提高临床疗效,更有效的缓解临床症状、改善生化指标、减轻炎性反应程度。 相似文献
63.
目的:探讨补脾益肾方联合温针灸治疗对重症肌无力(MG)疗效及对免疫功能的影响。方法:随机分配84例MG病例为西药组和针药组,每组各42例,西药组给予常规西药治疗,即泼尼松片中剂量冲击,小剂量隔日维持治疗,针药组基于以上用药基础给予补脾益肾方联合温针灸治疗,治疗3个月后,统计两组治疗前后的中医证候积分,评估两组中医证候疗效,对比治疗前后的颈部血管流速、T淋巴细胞亚群水平和血清可溶性白细胞介素6受体水平。结果:治疗后,两组中医证候积分显著降低,针药组的变化幅度大于西药组(P<0.05); 针药组的中医证候总有效率低于西药组(P<0.05); 治疗后,两组颈内动脉(ICA)、颈总动脉(CCA)、颈外动脉(ECA)显著提高(P<0.05),两组T淋巴细胞中CD3+、CD4+亚群所占比和CD8+、CD4+比值显著降低(P<0.05),两组血清slL-6R水平均显著降低(P<0.05),以上指标针药组变化幅度大于西药组(P<0.05)。结论:补脾益肾方联合温针灸治疗能缓解MG患者的中医证候症状,提高疗效,促进其颈部血管循环,纠正患者自身机体免疫功能紊乱。 相似文献
64.
目的:分析乳腺癌患者的CYP2D6基因多态性和代谢表型,为乳腺癌患者进行他莫西芬(TAM)个体化临床治疗提供参考依据。方法:选取2018年1月至2019年1月于我院乳腺科确诊的170例乳腺癌患者外周血,通过Sanger测序技术对CYP2D6基因的9个外显子进行全面具体分析。结果:本研究主要发现有5个CYP2D6等位基因变异位点:CYP2D6*10、CYP2D6*4、CYP2D6*7、CYP2D6*41和CYP2D6*5,其对应的发生频率分别为66.5%、5.9%、2.4%、0.6%和0.6%;其中,CYP2D6*10/*10基因型在乳腺癌患者中占据主导地位,发生频率为60.6%。结论:中国甘肃地区乳腺癌患者,多以CYP2D6*10等位基因、CYP2D6*10/*10基因型、TAM中间代谢型为主,这可为乳腺癌患者选择相应的个体化药物治疗方案以及本地区乳腺癌患者今后大规模的药物遗传基因组学研究提供参考数据。 相似文献
65.
Jingyi Wang Dandan Chen Wangzhao Song Zhiyong Liu Wenjuan Ma Xiaofeng Li Chao Zhang Xin Wang Yalei Wang Ye Yang Wenfeng Cao Lisha Qi 《Cancer science》2020,111(2):477-488
ATP6L, the C subunit of the V‐ATPase V0 domain, is involved in regulating the acidic tumor micro‐environment and may promote tumor progression. However, the expression and functional role of ATP6L in tumors have not yet been well explored. In this study, we found that ATP6L protein overexpression was related to colorectal cancer histological differentiation (P < 0.001), presence of metastasis (P < 0.001) and recurrence (P = 0.02). ATP6L expression in the liver metastatic foci was higher than in the primary foci (P = 0.04). ATP6L expression was notably concomitant with epithelial‐mesenchymal transition (EMT) immunohistochemical features, such as reduced expression of the epithelial marker E‐cadherin (P = 0.021) and increased expression of the mesenchymal marker vimentin (P = 0.004). Results of in vitro and in vivo experiments showed that ATP6L expression could alter cell morphology, regulate EMT‐associated protein expression, and enhance migration and invasion. The effect of ATP6L on metastasis was further demonstrated in a tail vein injection mice model. In addition, the mouse xenograft model showed that ATP6L‐overexpressing HCT116 cells grew into larger tumor masses, showed less necrosis and formed more micro‐vessels than the control cells. Taken together, our results suggest that ATP6L promotes metastasis of colorectal cancer by inducing EMT and angiogenesis, and is a potential target for tumor therapy. 相似文献
66.
Luyao Chen Yongpeng Xie Xin Ma Yu Zhang Xintao Li Fan Zhang Yu Gao Yang Fan Liangyou Gu Lei Wang Xu Zhang Bin Fu 《Molecular carcinogenesis》2020,59(10):1159-1173
Sex-determining region Y box (SOXs) are expressed in various cells and control cell fate and differentiation in a multitude of physiologic processes. SOX6, a main representative of SOXs, is involved in the regulation of carcinogenesis in various human malignancies. However, the role of SOX6 in clear cell renal cell carcinoma (ccRCC) remains unclear. In this study, SOX6 expression in ccRCC and its clinical significance were investigated. In vitro and in vivo assays were used to explore the tumor-related function and the underlying molecular mechanism of SOX6 in ccRCC. We confirmed that SOX6 was frequently downregulated in ccRCC tissues and cell lines. Besides, downregulation of SOX6 was significantly associated with larger tumor sizes, advanced tumor stage, higher Fuhrman grades, and its expression could act as an independent prognostic factor for ccRCC (hazards ratio = 0.590, P = .026). Gain/loss-of-function experiments demonstrated that SOX6 could remarkably inhibit tumor cell growth and foci formation in vitro and xenograft tumorigenesis in vivo, respectively. Mechanistically, SOX6 could influence cell cycle by regulating the G1/the S phase transition and had an inhibitory effect on Wnt/β-catenin signaling as well as its target genes, c-Myc and cyclin D1. Interesting, the tumor-suppressive function of SOX6 was proved to be dependent on its specific high-mobility-group (HMG) domain. In general, our findings indicated that SOX6 was a novel tumor suppressor and prognostic biomarker in ccRCC. SOX6 could inhibit tumor growth by negatively regulating the Wnt/β-catenin signaling pathway in an HMG domain-dependent manner in ccRCC, which might provide a novel therapeutic approach for ccRCC. 相似文献
67.
Many studies have shown a special interaction between LAG3 and PD-1 in T cell inhibition, while the co-expression and effect of LAG3 and PD-1 on T cells in breast cancer patients are still not very clear. Here, with strict exclusion criteria, 88 patients with breast cancer and 18 healthy controls were enrolled. The percentages of LAG3+PD-1+ T cells in their peripheral blood (PBL) and tumor infiltrating T cells (TIL) were analyzed by flow cytometry, which showed an increase in TILs but no difference in PBLs and presented differences in TILs in different molecular subtypes (P < 0.05). In triple-negative breast cancer (TNBC), the highest percentages were observed, while in ER+/PR+ breast cancer, the lowest percentages were observed; however, these percentages were not different in different clinical stages (P > 0.05). Immunohistochemical staining showed that the expression of their ligands, PD-L1, MHC class II molecular and FGL1, was inconsistent in different molecular subtypes and clinical stages. Analysis of the functions of T cells with different phenotypes showed that the proliferation and secretion capacity of LAG3+PD-1+ T cells was obviously exhausted, with more than a two-fold of decrease compared with the groups of single positive LAG3 or PD-1 (P < 0.05). Finally, in a mouse model of TNBC, the dual blockade of LAG3 and PD-1 was indicated to achieve a better anti-tumour effect than either one alone (P < 0.05), which may provide a new strategy for the immunoregulatory treatment of patients with TNBC in the future. 相似文献
68.
69.
70.